Peer-influenced content. Sources you trust. No registration required. This is HCN.

Low-Dose Erlotinib an Option for Frail or Elderly Patients w. NSCLC?

According to the results of a single-arm, multicenter phase 2 trial in JAMA Oncology, low-dose erlotinib may be a safe and effective option for frail or elderly patients with EGFR mutation-positive NSCLC.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form